- Active pathological bleeding
- Severe hypersensitivity reaction to Apixaban e.g., anaphylactic reactions
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
- Lesion or condition if considered a significant risk factor for major bleeding : Current or recent gastrointestinal ulceration
- Presence of malignant neoplasms at high risk of bleeding
- Recent brain or spinal injury or ophthalmic surgery
- Recent intracranial haemorrhage
- Known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.)